Project identifies molecules for tumor suppression

Scientists from the Cancer Research UK Manchester Institute at The University of Manchester say they have been working on finding new molecules that play a role in tumor suppression.

Investigators electrify antibiotic R&D field with claims of a breakthrough

Antibiotic R&D fell out of favor at Big Pharma companies years ago, chilling a field that only recently has shown signs of heating up with new development projects. But a transatlantic team of investigators electrified the field this week with its claims that a new antibiotic found in dirt was a potent killer of drug-resistant bacteria. And it could represent a new class of badly needed antibiotics that just might avoid the natural resistance that begins to evolve once a new antibiotic hits the market.

Team takes a new approach to taming neuroinflammation

A team at Scripps is identifying enzymes that influence production of an inflammatory lipid molecule in the brain, offering a prime target for drug developers and insights that may also assist investigators in fields involving brain inflammation, such as multiple sclerosis, Alzheimer's, Parkinson's and ALS.

Amgen teams with MD Anderson on new BiTE programs for MDS

Fast on the heels of the FDA's approval of Blincyto (blinatumomab), Amgen's new leukemia fighter that uses a bispecific T cell engager system to flag cancer cells for the immune system to destroy, the Big Biotech has partnered up with MD Anderson in Texas on a new program aimed at identifying targets for this technology in myelodysplastic syndrome.

Scientists uncover new target for triple-negative breast cancer

About one of every 5 cases of breast cancer are termed triple-negative. They are hard to treat and resistant to some of the therapies currently in use, and as a result patients in this subtype have a worse chance of beating the disease or delaying its progress significantly. But now a team of scientists in the U.K. says that they have identified a gene that appears to drive disease progression and might offer a good target for drug developers.

Scripps researchers find a better way to make a nicotine vaccine

An attempt by Nabi to develop a new nicotine vaccine failed decisively in clinical studies, chilling the field for researchers who once dreamed of coming up with a better way to break a habit that can kill people through any of 8 different cancers. But now a team at Scripps Research Institute believe they've cracked the biologic code that defeated NicVAX and discovered how you could develop a vaccine that works.

Mouse study points to a particular T cell target for diabetes, insulin resistance

Investigators at Baylor College of Medicine say that new animal research indicates that a certain type of T cell found in the immune system could be a good target for drug developers spotlighting Type 2 diabetes triggered by obesity as well as insulin resistance.

Cold Spring Harbor scientists find a biomarker for p53 cancer mutations

Investigators at Cold Spring Harbor Laboratory say they've identified a biomarker that can quickly highlight a potentially deadly mutation in p53, a natural tumor suppressor.

Nanotech particles can exterminate as well as tag cancer cells for surgeons

Researchers at Oregon State University have adapted a known molecule so that it sticks to cancer cells, opening up a new approach to better identifying tumors for surgical removal while providing a follow-up attack on any remaining malignant cells, helping to prevent the cancer from making a comeback.

Positive primate study for Parkinson's inspires a rally for Minerva

Animal studies typically don't do much for a biotech's stock price. Findings can be hard to replicate, animal models often don't translate well to human studies and hopeful signs seen at the preclinical stage can vanish in an instant--particularly in tough fields like neurodegeneration.

Johns Hopkins stem cell team tests out CRISPR tech, with encouraging results

CRISPR technology's potential for gene editing has helped inspire the launch of a trio of closely watched biotech startups with their sights set on some cutting-edge approaches to new therapeutics. And now a team at Johns Hopkins has done some experiments to demonstrate its promise in engineering human stem cell therapies.

CHOP scientists herald new approach to neurodegenerative diseases

A team at Children's Hospital of Philadelphia says they've debunked a common misconception about the mTORC1 pathway and come up with a new and better approach that has proved promising in an animal model of Huntington's disease.

Stem cell researchers claim Harvard, Brigham mishandled probe

Two prominent researchers whose work on stem cells has come under review have fired back at Harvard Medical School and Brigham & Women's Hospital in a lawsuit, blaming a coauthor for the problems that triggered one paper to be retracted and another questioned while claiming that the university mishandled its investigation into their efforts.

Stem cell investigator resigns in wake of controversy

Stem cell investigator Haruko Obokata has resigned from Japan's RIKEN Center for Developmental Biology some months after a paper she co-authored on a new method to create pluripotent stem cells was retracted.

Brown U dean points to a possible suspect driving metastasis

Dr. Jack Elias, dean of medicine and biological sciences at Brown University, has been studying the role of a protein called chitinase 3-like-1 in fibrosis and asthma for years. And now he says that new animal research indicates that this could also be a good target for cancer metastasis.

New research points to a key driver--and drug target--behind hepatitis infections

While studying the effects and causes of hepatitis C infection of the liver, a group of scientists at Aarhus University in Denmark say they discovered a key driver of the disease that could prove particularly effective in helping patients with hard-to-treat cases.

Northwestern team claims they found the right way to ID Alzheimer's early on

Longtime Alzheimer's researcher William Klein led a team of investigators at Northwestern University which developed a new imaging technology they say can flag the neurodegenerative disease at a very early stage of development, possibly highlighting a fresh approach for developing new therapies as well as testing them at a point when treatments may still be effective.

J&J, Lundbeck spearhead an R&D consortium focused on depression, neurodegeneration

Johnson & Johnson and Lundbeck are throwing some scientific muscle behind a new initiative at the Wellcome Trust which enlisted researchers at 7 top academic research institutions in an effort to determine what role the immune system and inflammation play in depression and neurodegenerative diseases like Alzheimer's.

Investigators hit on a new class of stem cells

A research team says it has developed a new type of stem cell--capable of developing into any kind of tissue--that could pave the way to new cell lines that could be made more efficiently, opening up its potential in R&D.

Repurposed fibroblasts may open the door to new melanoma drugs, screening tech

Researchers have hit on a new approach to creating functional melanocytes, the body's pigment-producing cells. And their work could spur a fresh approach to screening and developing new drugs for melanoma as well as producing new cell-based therapies for a variety of skin diseases.